Add Company
Join Now

VectorY Revenue and Competitors

License our Company Data API

Amsterdam, Netherlands

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • VectorY's estimated annual revenue is currently $13.9M per year.(i)
  • VectorY's estimated revenue per employee is $155,000

Employee Data

  • VectorY has 90 Employees.(i)
  • VectorY grew their employee count by -13% last year.

VectorY's People

NameTitleEmail/Phone
1
Head Manufacturing StrategyReveal Email/Phone
2
Head Process DevelopmentReveal Email/Phone
3
Director Antibody TechnologyReveal Email/Phone
4
Chief Corporate OfficerReveal Email/Phone
5
Consultant Medical DirectorReveal Email/Phone
6
Chief Scientific OfficerReveal Email/Phone
7
Intellectual Property ManagerReveal Email/Phone
8
Junior technician DSPReveal Email/Phone
9
Senior TechnicianReveal Email/Phone
10
Team-Lead Translational Biology | Senior Scientist BiomarkersReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7M45-34%N/AN/A
#2
$10.4M67-7%N/AN/A
#3
$10.2M666%N/AN/A
#4
$6.7M43-2%N/AN/A
#5
$23.3M150-18%N/AN/A
#6
$35.8M2319%N/AN/A
#7
$11.2M72-18%N/AN/A
#8
$15.2M983%N/AN/A
#9
$1.7M11-52%N/AN/A
#10
$10.1M657%N/AN/A
Add Company

What Is VectorY?

VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for large disease areas of high unmet medical need. By combining state-of-the-art technologies and novel and scientific concepts, VectorY's mission is to bring innovative therapies to patients worldwide. Founded in August 2020, and based in the Amsterdam Science Park, VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics such as vectorized antibodies for both CNS and somatic disorders, with a special focus on muscle diseases. With R&D and manufacturing facilities in Amsterdam, VectorY develops proprietary & partnered programs based on its novel AAV-based vectorized antibody & gene therapy platform. Product candidates are based on new vector technologies, which will enable the next generation of highly scalable manufacturing processes within VectorY's own manufacturing facilities. Our manufacturing capabilities will include a state-of-the-art multi-product GMP facility in the Netherlands, with the capability to deliver suspension based AAV viral vector manufacturing of up to 2000L for both clinical and commercial supply.

keywords:N/A

N/A

Total Funding

90

Number of Employees

$13.9M

Revenue (est)

-13%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$24.3M900%N/A
#2
$7.5M907%N/A
#3
$24.3M90-4%N/A
#4
$18.9M9025%N/A
#5
$16.2M90-29%N/A